The Kitalys Institute Board of Directors
G. Alexander Fleming, MD, Chairman/President
G. Alexander Fleming, MD
Dr. Alexander Fleming is Founder and Executive Chairman of Kinexum. He is also President and Chief Executive Officer of Tolerion, a biotechnology company developing “disease-modifying” treatments for type 1 diabetes and other autoimmune diseases.
Dr. Fleming received his M.D. and internal medicine training from Emory. He completed fellowship training in endocrinology at Vanderbilt and metabolism at National Institutes of Health, where he was a senior fellow.
At the US Food and Drug Administration from 1986-98, Dr. Fleming was responsible for the therapeutic areas of diabetes, other metabolic and endocrine disorders, growth and development, nutrition, lipid-lowering compounds, and reproductive indications.
He led reviews of landmark approvals, including metformin and the first statin, insulin analog, PPAR-agonist, and growth hormone for non-GH deficiency indications.
Dr. Fleming coined the term “Metabesity,” which refers to the constellation of cancer, heart and neurologic diseases, diabetes, and the aging process itself, all of which share common metabolic root causes and potential preventive therapies. He organized the first Congress on Metabesity in London in October 2017, followed by the second Congress in Washington, D.C., in 2019, and now the third Congress in 2020.
Thomas Seoh, JD, Vice-President/Treasurer
Thomas Seoh is an entrepreneur and executive who has held senior leadership positions in public and private, pharmaceutical, biotech and medical device companies for over 25 years.
After practicing corporate law in New York and London and serving as General Counsel for the North American holding company for Australian billionaire Kerry Packer, he held legal management positions in the ICN Pharmaceuticals group of companies in Costa Mesa, which developed the antiviral, VIRAZOLE®. He next joined Guilford Pharmaceuticals in Baltimore, which commercialized GLIADEL® wafer for glioblastoma multiforme and developed the propofol pro-drug LUSEDRA®, first as VP, General Counsel and Secretary, and later as SVP Corporate and Commercial Development. He was then CEO of venture-backed Faust Pharmaceuticals in Strasbourg, France, developing drug candidates for Parkinson’s disease and Duchenne muscular dystrophy patients. He additionally served on the board or leadership teams of medical device companies working on ex vivo liver dialysis, mechanical thrombectomy and a skin substitute. He joined Kinexum as CEO in 2017.
Thomas holds an AB in Philosophy and History and a JD from Harvard University.
Adriane Berg, JD, Director/Secretary
Adriane Berg is an influencer for successful aging, healthy longevity and lifelong contribution.
She is a prolific writer, international keynote speaker and founder of Generation Bold Consulting to reach the boomer, mature and caregiver markets. Ms. Berg acts as director of Metabesity2020, an annual conference and initiative to increase healthy longevity and delay or prevent age-related diseases.
Ms. Berg is host of the podcast Generation Bold: The Fountain of Truth, winner of the Mature Market Award for Radio. She is a New York Times Age Boom Fellow and author of 14 books, including The Retirement Income Explosion.
She is a well-known advocate for successful aging and a tireless fighter against ageism, with multiple appearances on the Oprah Winfrey Show, Good Morning America and other national shows.
She is also an attorney and helped found the National Academy of Elder Law Attorneys, advancing the concepts of longevity planning and longevity law in the financial and legal professions.
David Fox, JD, Counsel
David Fox is a leading authority on the regulation of prescription and over-the-counter drugs, biological products, combination products, and controlled
He advises management teams, from start-ups to the largest global pharmaceutical and biotechnology companies, on matters before the Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA).
David is closely integrated with funding sources for the industry and is frequently retained as a strategic advisor on assessing the value of life sciences assets.
Known for his collaborative approach to complex regulatory issues, David has successfully resolved numerous disputes between sponsors and staff at FDA on products that raise novel regulatory issues.
Peter Anderson, Futurist